Floatz logo

Patupilone

Recurrent Glioblastoma Planned for Reoperation

University of ZurichSmall moleculePhase 1/2Dormant
CCC
52/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
37/ 100
Competitive Position
95/ 100

Competitive context

354 Active assets in the Recurrent Glioblastoma Planned for Reoperation cohort.

Asset / SponsorPhaseRating
Irinotecan
Beijing Sanbo Brain Hospital
Phase 2/3BBB
Depatuxizumab Mafodotin
AbbVie
Phase 3BB
(+)-VINCRISTINE
University of Cincinnati
Phase 3BB
CARMUSTINE
Leland Metheny
Phase 3BB
Irinotecan
University of Cincinnati
Phase 3BB

View all 50 →

Same molecule, other indications

Patupilone is also rated in:

peritoneal neoplasmDormant
BB
Indicative ·
64 / 100
View asset →
cancerDormant
B
Indicative ·
58 / 100
View asset →
non-small cell lung carcinomaDormant
B
Indicative ·
58 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →